Auxilium Pharmaceuticals, Inc. today said the U.S. Food and Drug Administration granted priority review status to its biologics license application for Xiaflex to treat Dupuytren's contracture.

Auxilium Pharmaceuticals, Inc. today said the U.S. Food and Drug Administration granted priority review status to its biologics license application for Xiaflex to treat Dupuytren's contracture.